The clinical goal for contrast-enhanced CT examinations is to achieve diagnostic contrast enhancement in the target region of interest, says Bayer. Contrast enhancement is influenced by patient, contrast medium and scanner factors. The most important patient-related factor affecting the magnitude of vascular and parenchymal contrast enhancement is body weight, since different body weights can influence enhancement when using a fixed injection protocol. “A shift from fixed to personalised protocols should be the ultimate objective,” the company explains. “The goal of individualising contrast protocols is a more consistent enhancement.
“While patient body weight is a key factor in CT imaging principles, we mustn’t forget other factors that have an impact, such as contrast medium dosing factors, iodine delivery rates and variable CT tube voltages. With so many principles to consider, how can today’s busy CT departments realise the goal of individualising contrast protocols?”
In line with its commitment to personalised imaging, Bayer has introduced a premium clinical application service. Centargo Cardio is designed to give imaging professionals the ability to create a tailored cardiac CT imaging practice for their institutions, supporting high quality cardiac CT angiography (CCTA) imaging results and improved patient care. Bayer’s goals are to work with institutes to better understand their cardiac imaging needs and CCTA routine, to co-create tailored protocols, implement these protocols and together measure the image quality of these protocols compared to baseline.
Picture: Centargo Cardio is designed to give imaging professionals the ability to create tailored cardiac CT imaging.
Visit Bayer at UKIO on stand B11/12.
This news story has been sponsored by the companies concerned and does not represent the views or opinions of RAD Magazine. Visit our dedicated UKIO conference page to find out more.
